Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) CMO Elliot Ehrich sold 16,667 shares of the company’s stock on the open market in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $47.41, for a total transaction of $790,182.47. Following the completion of the sale, the chief marketing officer now directly owns 22,973 shares in the company, valued at approximately $1,089,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 1.21% during mid-day trading on Friday, hitting $48.38. The stock had a trading volume of 374,217 shares. Alkermes Plc has a one year low of $28.86 and a one year high of $54.25. The stock has a 50-day moving average of $48.25 and a 200-day moving average of $46.7. The company’s market cap is $6.992 billion.

Alkermes Plc (NASDAQ:ALKS) last released its earnings data on Wednesday, April 30th. The company reported $0.11 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter last year, the company posted $0.40 earnings per share. Alkermes Plc’s revenue was down 20.3% compared to the same quarter last year. On average, analysts predict that Alkermes Plc will post $0.49 earnings per share for the current fiscal year.

A number of research firms have recently commented on ALKS. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday. They now have a $50.00 price target on the stock. Separately, analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Alkermes Plc has an average rating of “Buy” and an average target price of $49.50.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.